AU8238482A – Calcium-antagonist composition
– Google Patents
AU8238482A – Calcium-antagonist composition
– Google Patents
Calcium-antagonist composition
Info
Publication number
AU8238482A
AU8238482A
AU82384/82A
AU8238482A
AU8238482A
AU 8238482 A
AU8238482 A
AU 8238482A
AU 82384/82 A
AU82384/82 A
AU 82384/82A
AU 8238482 A
AU8238482 A
AU 8238482A
AU 8238482 A
AU8238482 A
AU 8238482A
Authority
AU
Australia
Prior art keywords
active compound
calcium
antagonistic
antagonist composition
sustaining dose
Prior art date
1981-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU82384/82A
Other versions
AU555093B2
(en
Inventor
Volker Buehler
Heinz Einig
Winfried Koch
Joachim Arthur Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1981-04-07
Filing date
1982-04-06
Publication date
1982-10-14
Family has litigation
First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=6129505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU8238482(A)
«Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
1982-04-06
Application filed by BASF SE
filed
Critical
BASF SE
1982-10-14
Publication of AU8238482A
publication
Critical
patent/AU8238482A/en
1986-09-11
Application granted
granted
Critical
1986-09-11
Publication of AU555093B2
publication
Critical
patent/AU555093B2/en
2002-04-06
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K9/00—Medicinal preparations characterised by special physical form
A61K9/20—Pills, tablets, discs, rods
A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/275—Nitriles; Isonitriles
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Abstract
1. A pharmaceutical composition which contains a calcium-antagonistic active compound, with or without additional active compounds, is intended for oral administration to produce a sustained action for continuous therapy and contains only the sustaining dose of active compound, bound to pharmaceutical auxiliaries, wherein the calcium-antagonistic active compound is Gallopamil or Verapamil and wherein, at the sustaining dose, the ratio of the constituents with rapid release of active compound to those with sustained release of active compound is from 1 : 0.6 to 1 : 6.
AU82384/82A
1981-04-07
1982-04-06
Calcium-antagonist composition
Ceased
AU555093B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
DE31139019
1981-04-07
DE19813113901
DE3113901A1
(en)
1981-04-07
1981-04-07
ACTIVE SUBSTANCE PREPARATION FOR ORAL APPLICATION
Publications (2)
Publication Number
Publication Date
AU8238482A
true
AU8238482A
(en)
1982-10-14
AU555093B2
AU555093B2
(en)
1986-09-11
Family
ID=6129505
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU82384/82A
Ceased
AU555093B2
(en)
1981-04-07
1982-04-06
Calcium-antagonist composition
Country Status (17)
Country
Link
EP
(1)
EP0063266B1
(en)
JP
(1)
JPS57175113A
(en)
AT
(1)
ATE14076T1
(en)
AU
(1)
AU555093B2
(en)
CA
(1)
CA1184497A
(en)
DE
(2)
DE3113901A1
(en)
DK
(1)
DK157482A
(en)
ES
(1)
ES511208A0
(en)
FI
(1)
FI821253L
(en)
GR
(1)
GR74770B
(en)
HU
(1)
HU186855B
(en)
IE
(1)
IE52985B1
(en)
IL
(1)
IL65328A
(en)
NO
(1)
NO157204C
(en)
NZ
(1)
NZ200244A
(en)
PT
(1)
PT74705B
(en)
ZA
(1)
ZA822327B
(en)
Families Citing this family (16)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4461759A
(en)
*
1983-01-03
1984-07-24
Verex Laboratories, Inc.
Constant release rate solid oral dosage formulations of veropamil
US4874614A
(en)
*
1985-03-25
1989-10-17
Abbott Laboratories
Pharmaceutical tableting method
US4863741A
(en)
*
1985-03-25
1989-09-05
Abbott Laboratories
Tablet composition for drug combinations
LU86077A1
(en)
*
1985-09-18
1987-04-02
Pharlyse Sa
NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
LU86099A1
(en)
*
1985-09-30
1987-04-02
Pharlyse
EXTENDED RELEASE GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM
IE58401B1
(en)
*
1986-06-20
1993-09-08
Elan Corp Plc
Controlled absorption pharmaceutical composition
US4981871A
(en)
*
1987-05-15
1991-01-01
Abelson Mark B
Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A
(en)
*
1987-07-28
1988-12-20
E. R. Squibb & Sons, Inc.
Controlled release formulation
DE3809764A1
(en)
*
1988-03-23
1989-10-05
Knoll Ag
MIXTURE OF ALGINATES AND POLYACRYLATES AND THEIR USE
US5230901A
(en)
*
1988-03-23
1993-07-27
Knoll Ag
Sustained release tablet of a mixture of alginates and polyacrylates
WO1990000391A1
(en)
*
1988-07-13
1990-01-25
Knoll Aktiengesellschaft
Depot-form of an alginate-based drug
US5032406A
(en)
*
1989-02-21
1991-07-16
Norwich Eaton Pharmaceuticals, Inc.
Dual-action tablet
DE3932378A1
(en)
*
1989-09-28
1991-04-11
Knoll Ag
SOLID MEDICAL FORM WITH A HIGH VERAPAMIL CONTENT
IT1264696B1
(en)
*
1993-07-09
1996-10-04
Applied Pharma Res
PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US5695781A
(en)
*
1995-03-01
1997-12-09
Hallmark Pharmaceuticals, Inc.
Sustained release formulation containing three different types of polymers
US6083532A
(en)
1995-03-01
2000-07-04
Duramed Pharmaceuticals, Inc.
Sustained release formulation containing three different types of polymers and tablet formed therefrom
Family Cites Families (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
DE1154810B
(en)
*
1961-04-01
1963-09-26
Knoll Ag
Process for the preparation of basic substituted phenylacetonitriles
DE1467781A1
(en)
*
1963-07-15
1968-12-05
Boehringer Sohn Ingelheim
Process for the production of coated tablets with extended release of active ingredients
1981
1981-04-07
DE
DE19813113901
patent/DE3113901A1/en
not_active
Withdrawn
1982
1982-02-22
GR
GR67376A
patent/GR74770B/el
unknown
1982-03-23
IL
IL65328A
patent/IL65328A/en
unknown
1982-03-23
CA
CA000399116A
patent/CA1184497A/en
not_active
Expired
1982-03-31
EP
EP82102695A
patent/EP0063266B1/en
not_active
Expired
1982-03-31
DE
DE8282102695T
patent/DE3264519D1/en
not_active
Expired
1982-03-31
NO
NO821084A
patent/NO157204C/en
unknown
1982-03-31
AT
AT82102695T
patent/ATE14076T1/en
active
1982-04-01
JP
JP57052378A
patent/JPS57175113A/en
active
Pending
1982-04-05
PT
PT74705A
patent/PT74705B/en
unknown
1982-04-05
ZA
ZA822327A
patent/ZA822327B/en
unknown
1982-04-06
DK
DK157482A
patent/DK157482A/en
not_active
Application Discontinuation
1982-04-06
NZ
NZ200244A
patent/NZ200244A/en
unknown
1982-04-06
IE
IE812/82A
patent/IE52985B1/en
unknown
1982-04-06
AU
AU82384/82A
patent/AU555093B2/en
not_active
Ceased
1982-04-06
HU
HU821058A
patent/HU186855B/en
not_active
IP Right Cessation
1982-04-06
ES
ES511208A
patent/ES511208A0/en
active
Granted
1982-04-07
FI
FI821253A
patent/FI821253L/en
not_active
Application Discontinuation
Also Published As
Publication number
Publication date
NO157204B
(en)
1987-11-02
GR74770B
(en)
1984-07-12
DE3264519D1
(en)
1985-08-08
AU555093B2
(en)
1986-09-11
NO821084L
(en)
1982-10-08
IL65328A0
(en)
1982-05-31
DK157482A
(en)
1982-10-08
PT74705A
(en)
1982-05-01
CA1184497A
(en)
1985-03-26
DE3113901A1
(en)
1982-10-28
HU186855B
(en)
1985-10-28
FI821253L
(en)
1982-10-08
EP0063266A3
(en)
1983-05-04
EP0063266B1
(en)
1985-07-03
JPS57175113A
(en)
1982-10-28
NZ200244A
(en)
1984-08-24
ATE14076T1
(en)
1985-07-15
ES8307496A1
(en)
1983-08-16
IE820812L
(en)
1982-10-07
PT74705B
(en)
1983-11-14
IL65328A
(en)
1985-06-30
FI821253A0
(en)
1982-04-07
NO157204C
(en)
1988-02-10
ES511208A0
(en)
1983-08-16
EP0063266A2
(en)
1982-10-27
IE52985B1
(en)
1988-04-27
ZA822327B
(en)
1983-03-30
Similar Documents
Publication
Publication Date
Title
AU555093B2
(en)
1986-09-11
Calcium-antagonist composition
EP0427247A3
(en)
1992-01-02
Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
TW234691B
(en)
1994-11-21
AU2246292A
(en)
1992-12-21
Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
DE60022895D1
(en)
2006-02-09
PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
DE3566545D1
(en)
1989-01-05
2-substituted-1,3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
KR830002510A
(en)
1983-05-30
Composition consisting of biologically active compound and hydroxyalkyl starch
DK0629400T3
(en)
2000-02-14
Idebenone-containing preparations for the treatment of Alzheimer's disease
EP0136464A3
(en)
1985-07-03
Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
CA2078869A1
(en)
1991-09-24
Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
KR890004705A
(en)
1989-05-09
Antiviral agents
ATE18203T1
(en)
1986-03-15
(-)-15-DEOXYSPERGUALIN, ITS MANUFACTURE AND MEDICATIONS CONTAINING THIS ACTIVE SUBSTANCE.
ATE85218T1
(en)
1993-02-15
ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF HYPERTENSION WITH DILTIAZEM HYDROCHLORIDE ONCE DAILY.
WO1987003590A1
(en)
1987-06-18
Medicament for the treatment of diseases of the liver
IL87867A
(en)
1992-11-15
Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
IE780530L
(en)
1978-09-17
Anti-histamine salts and compositions
JPS54126737A
(en)
1979-10-02
Antithrombotic agent
ATE15041T1
(en)
1985-09-15
ANTI-PAIN RELIEF, ANTI-INFLAMMATORY AND ANTIPYREXIC COMPOUND, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2567755B1
(en)
1988-08-12
NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT
None